Synthesis Capital holds USD 300m final close for debut fund
London-headquartered Synthesis Capital has held a final close for its debut food technology and alternative protein-focused fund on USD 300m.
More on Venture
Nation 1 launches new early-stage, EUR 35m-EUR 40m fund
Czech investor targets first close in 1Q24, seeking to attract institutional investors and at least one bank
Beyond Impact aims for EUR 100m close for alternative protein fund
Article 9 fund held EUR 25m first close in early 2022; targets stakes in non-animal proteins and ingredients
Women in VC: Turenne Santé’s Chaoui on new healthcare growth strategy and social impact
Healthcare sponsor aims to raise EUR 150m for new growth fund, with further deployment and fundraising for its LBO strategy in the pipeline
Nekko aims to reach EUR 10m hard-cap for N Venture I within six months
Spanish VC firm plans to build on the vehicle’s EUR 6m first close, with nine companies backed so far
Latest News
Quadrivio plans first close for EUR 500m Lifestyle Fund II by mid-2023
Italy-based GP will expand predecessor Made in Italy vehicle’s focus beyond Italy to target European SMEs
AnaCap reaps 4.3x on MRH Trowe minority stake sale to TA Associates
German insurance broker will now be backed by both GPs; deal comes 2.5 years into AnaCap's investment period
Bregal poaches Carlyle exec for new chief investment officer role
Ryan Selwood’s appointment follows other recent senior hires, including a chief people officer and a chief technology officer
Cinven’s indicative EUR 10 per share Synlab bid seen as below fair value
Sponsor listed the laboratory testing service provider at EUR 18 per share in 2020